Gut and lung bacteria could predict immunotherapy success in lung cancer

NCT ID NCT04063501

Recruiting now Knowledge-focused Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at 48 adults with advanced lung cancer who are about to start immunotherapy. Researchers will collect samples from the lungs, stool, and blood before and after treatment to see if certain bacteria are linked to better outcomes. The goal is to understand why some people respond well to immunotherapy while others do not.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which lung cancer patients will benefit from immunotherapy, leading to more personalized treatment plans.
What could go wrong: This is an early observational study with only 48 participants, so results may not apply to all patients. It does not test a new treatment, so no direct benefit to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

NYU Langone Health
RECRUITING

New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.